Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article
Open Access

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

Marco Pirazzini, Ornella Rossetto, Roberto Eleopra and Cesare Montecucco
Jeffrey M. Witkin, ASSOCIATE EDITOR
Pharmacological Reviews April 2017, 69 (2) 200-235; DOI: https://doi.org/10.1124/pr.116.012658
Marco Pirazzini
Department of Biomedical Sciences, University of Padova, Italy (M.P., O.R., C.M.); Neurologic Department, University-Hospital S. Maria della Misericordia, Udine, Italy (R.E.); and Consiglio Nazionale delle Ricerche, Institute of Neuroscience, University of Padova, Italy (C.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ornella Rossetto
Department of Biomedical Sciences, University of Padova, Italy (M.P., O.R., C.M.); Neurologic Department, University-Hospital S. Maria della Misericordia, Udine, Italy (R.E.); and Consiglio Nazionale delle Ricerche, Institute of Neuroscience, University of Padova, Italy (C.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Eleopra
Department of Biomedical Sciences, University of Padova, Italy (M.P., O.R., C.M.); Neurologic Department, University-Hospital S. Maria della Misericordia, Udine, Italy (R.E.); and Consiglio Nazionale delle Ricerche, Institute of Neuroscience, University of Padova, Italy (C.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cesare Montecucco
Department of Biomedical Sciences, University of Padova, Italy (M.P., O.R., C.M.); Neurologic Department, University-Hospital S. Maria della Misericordia, Udine, Italy (R.E.); and Consiglio Nazionale delle Ricerche, Institute of Neuroscience, University of Padova, Italy (C.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey M. Witkin
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure of BoNT/A1 and BoNT/B1 molecules. Crystal structures of BoNT/A1 (PDB ID: 3BTA) (Lacy et al., 1998) (A) and BoNT/B1 (PDB ID: 1EPW) (Swaminathan and Eswaramoorthy, 2000) (B) represented as space-filling models of the two opposite surfaces of each toxin molecule showing the organization of the three toxin domains: the neurospecific binding HC-C subdomain (green), the lectin-like HC-N subdomain (purple), the translocation HN domain (yellow), and the metalloprotease L domain (red). The pink cavity in the HC-C subdomains shown in the lower panels is the polysialoganglioside binding site. A peptide belt (shown in blue) surrounding the L domain and the interchain disulfide bond (white in the upper panels) linking the L and HN domain, which stabilize the structure, is also shown.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Structure of BoNTA1-NTNHA1 heterodimer and of the progenitor toxin complex (PTC). (A) Crystal structure of BoNT/A1 in complex with the NTNHA/A1 protein (PDB ID: 3V0B) (Gu et al., 2012) represented as space-filling models of the two opposite surfaces. For BoNT/A1, the L chain is in red, the HN domain is in yellow, and in green the HC domain. The BoNT/A1 protein binds “hand in hand” the NTNHA/A1 protein whose domain structure and organization are very similar to that of the toxin (see central inset for a simplified scheme). For NTNHA/A1 nL is in orange, nHN in pink, and nHC in light green. In blue and in light orange are the belts of toxin and NTNHA, respectively. Notice that NTNHA/A1 shields a large part of the BoNT surface. A similar structure has been determined for BoNT/E1 (PDB ID: 4ZKT) (Eswaramoorthy et al., 2015). (B) Space-filling representation of the large precursor toxin complex (PTC), which has a triskelion-like structure (Amatsu et al., 2013; Lee et al., 2013). BoNT/A1 (red) interacts with NTNHA/A1 (orange) but has no contacts with HA proteins. There are six HA33 proteins (blue), three HA17 proteins (light blue), and three HA70 proteins (pink) in each NTNHA/A1-BoNT/A1 complex. Because the HA proteins do not contact the BoNT/A1 molecule, they are unlikely to play any protective role on BoNT/A1, as previously proposed. Rather, the structure suggests a role as adhesin molecule (see text). Similar structures have been determined for BoNT/D and BoNT/B1 using single particle electron microscopy (Benefield et al., 2013; Hasegawa et al., 2007). The structure of (B) was assembled by joining the structure of the BoNT/A1-NTNHA/A1 heterodimer (PDB ID: 3V0B) and the structure of the triskelion (PDB ID: 3WIN).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Cleavage sites of the neuronal SNARE proteins by the different BoNT types and subtypes. The BoNT proteolytic activity is highly specific and directed toward unique peptide bonds within the sequence of their respective SNARE protein targets. VAMP of the synaptic vesicle (in blue, isoform 1 is shown here) or SNAP-25 (in green) or syntaxin (in red, isoform 1B is shown here) mainly localized on the cytosolic side of the presynaptic membrane. Available evidence indicate that all the toxin subtypes and chimeric toxins cleave the same SNARE substrate, although different subtypes may cleave different peptide bonds. For example BoNT/F5 and BoNT/FA, a chimeric toxin derived from a genetic recombination between BoNT/F2, /F5, and A1 neurotoxin genes, cleave VAMP at a peptide bond different from the one cleaved by BoNT/F1. Notice that tetanus neurotoxin and botulinum B1 neurotoxin cleave the same target at the same site proving that the different symptoms of tetanus and botulism are not due to a different target molecule, but to different neuronal targets: the Renshaw cells of the spinal cord for tetanus neurotoxin and peripheral nerve terminals for BoNT/B1.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    The nerve terminal intoxication by botulinum neurotoxins is a multi-step process. The first step (1) is the binding of the HC domain (green) to a polysialoganglioside (PSG) receptor of the presynaptic membrane (gray and black), followed by binding to a protein receptor. The currently known protein receptors are i) synaptotagmin (Syt, gray) for BoNT/B1, /DC, and /G; ii) glycosylated SV2 (black with its attached N-glycan in pink) for BoNT/A1 and /E1. Syt may be located either within the exocytosed synaptic vesicle or on the presynaptic membrane. The BoNT is then internalized inside SVs, which are directly recycled (2a) or inside SVs that fuse with the synaptic endosome and re-enter SV cycle by budding from this intermediate compartment (2b). The acidification (orange) of the vesicle, operated by the v-ATPase (orange), drives the accumulation of neurotransmitter (blue dots) via the vescicular neurotransmitter transporter (light blue). The protonation of BoNT leads to the membrane translocation of the L chain into the cytosol (3), which is assisted by the HN domain (yellow). The L chain (red) is released from the HN domain by the action of the thioredoxin reductase-thioredoxin system (TrxR-Trx, blue and dark blue) and Hsp90 (mud color), which reduce the interchain disulfide bond (orange) and avoid the aggregation of the protease (4). In the cytosol, the L chain displays its metalloprotease activity: BoNT/B, /D, /F, /G cleave VAMP (blue); BoNT/A and BoNT/E cleave SNAP-25 (green); and BoNT/C cleaves both SNAP-25 and syntaxin (Stx, dark red) (5). Each of these proteolytic events is sufficient to cause a prolonged inhibition of neurotransmitter release with consequent neuroparalysis.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Close-up views of the binding interfaces between BoNT/A1 and BoNT/B1 to their synaptic vesicle protein receptors. (A) Two areas of interaction of BoNT/A1 with the synaptic vesicle protein glycosylated-SVC2 (PDB ID 5JLV). One main interaction is mediated by protein-protein contacts through the pairing of the backbones of two solvent-exposed β-strands (black dotted ellipsoid), one from each partner. Essential interactions are mediated by R1156 of BoNT/A1 making a cation-π stacking interaction with P563 of SV2C and also by R1294 of the toxin. The second main interaction is mediated by N559 whose side chain carries a N-glycan modification (shown as sticks), which fits within a crevice formed at the interface between HC-N (purple) and HC-C (green). Amino acids forming the groove are colored in cyan and labeled according to their location (P953, N954, S957, S1062, H1064, and R1065 from HC-N, in purple and T1145, Y1155, D1288, D1289, and G1292 from HC-C, in green). The cartoon also shows essential water molecules (black pellets) and the H bonds (yellow dotted lines), which mediate the interaction of BoNT/A1 with the N-glycan, suggesting the possibility that they serve to adapt the variety of N-glycans that are produced by different kind of neurons and/or by neurons of different individuals and animal species. (B) Interaction among BoNT/B1 and its synaptic vesicle protein receptors Synaptotagmin II (Syt-II) (PDB ID 4KBB). The interface of interaction is at the extreme bottom of BoNT/B and, at variance from BoNT/A1, involves exclusively HC-C (green). Syt-II is unstructured in solution but assumes an helical conformation upon binding to the toxin, forced by the interactions occurring at the level of two hydrophobic pockets. One pocket is formed by HC-C residues P1117, W1178, Y1181, P1194, A1196, P1197, F1204 with Syt-II residues M46, F47, and L50. The second pocket of HC-C is lined by residues K1113, S1116, P1117, V1118, Y1183, E1191, K1192, F1194, and F1204 with Syt-II residues F54, F55, E57, and I58. Only the most significant aminoacids involved in the interaction are shown and labeled. Note the H bond (black dotted line) formed by K1113 and E57, which may also interact electrostatically. The binding sites for the oligosaccharide portion of polysialoganglioside receptor are not shown, but in both BoNT/A1 and /B1 are located within the HC-C subdomain at a distance from the protein receptor binding sites in such a position that they do not interact with them (see text).

Tables

  • Figures
    • View popup
    TABLE 1

    Sequence alignment of mouse, rat, and human VAMP isoforms and cleavage sites of the different BoNTs

    The SNARE motifs of mouse, rat, and human VAMP isoforms have been aligned using http://www.uniprot.org/align/. The conserved cleavage sites of VAMP isoforms targeted by specific BoNT types and subtypes are in the same color of the respective toxins. The cleavage site of the newly identified BoNT-like metalloprotease of Weissella oryzae (WO) is also shown (purple). Conserved proteolytic sites whose susceptibility to cleavage is predicted, but not experimentally proven, are underlined with the color of the respective BoNT. Nonconserved cleavage sites are underlined in black as well as conserved cleavage sites, which were experimentally found to be noncleavable. When known, the recognition motif, used by the toxin to bind the substrate in addition to the cleavage sites (Rossetto et al., 1994), is underlined in red.

    Embedded Image
    • View popup
    TABLE 2

    Sequence alignment of mouse, rat, and human SNAP25 isoforms and cleavage sites of the different BoNTs

    The C-terminal SNARE motif of mouse, rat, and human SNAP isoforms have been aligned using http://www.uniprot.org/align/. The conserved cleavage sites targeted by specific BoNT types and subtypes are colored like the respective toxin. Conserved cleavage sites whose susceptibility to cleavage is predicted, but not experimentally proven, are underlined with the color of the respective BoNT. Nonconserved cleavage sites are underlined in black as well as conserved cleavage sites that were experimentally found to be noncleavable. Notice that mouse SNAP-23 has a cleavage site for BoNT/E different from the one present in SNAP-25, which is anyhow cleaved, whereas human SNAP-23, which has the same proteolytic site as SNAP-25, is not cleaved (Vaidyanathan et al., 1999). Similarly, mouse SNAP-23 was reported to be cleaved by BoNT/A, although the peptide bond is not conserved. At the same time, BoNT/C, whose cleavage site is conserved (also in human SNAP-23) does not cleave mouse SNAP-23. The cleavability of rat SNAP-23 was predicted on these premises. When known, the recognition motif used by the toxin to bind the substrate in addition to the cleavage sites (Rossetto et al., 1994) is underlined in red.

    Embedded Image
    • View popup
    TABLE 3

    Sequence alignment of mouse, rat, and human Syntaxin isoforms and cleavage site of BoNTs

    The C-terminal SNARE motifs of mouse, rat, and human syntaxin isoforms are aligned using http://www.uniprot.org/align/. BoNT/C conserved cleavage sites are shown in purple. Conserved cleavage sites whose susceptibility to cleavage is predicted, but not experimentally proven, are underlined in purple. Nonconserved cleavage sites are underlined in black.

    Embedded ImageEmbedded Image
    • View popup
    TABLE 4

    Comparison of botulinum neurotoxin products marketed in Europe and North America

    Units are manufacturer specific and are not interchangeable.

    Botox/VistabelDysport/AzzalureXeomin/BocoutureNeurobloc/Myobloc
    Generic nameOnabotulinumtoxinAAbobotulinumtoxinAIncobotulinumtoxinARimabotulinumtoxinB
    ManufacturerAllergan (USA)Ipsen Pharmaceuticals (France)Merz Pharmaceuticals (Germany)US WorldMeds (USA)
    C. botulinum strainHall A-hyperHall AHall A (ATCC 3502)Bean
    Toxin typeA1A1A1B1
    MW900 kDa complexMW not reported150 kDaMW not reported
    (PTCs)(Yes)(Yes)None(Yes)
    Pharmaceutical formVacuum-dried powder for reconstitutionFreeze-dried powder for reconstitutionFreeze-dried powder for reconstitutionReady-to-use solution
    Shelf life2–8°C2–8°CRoom temperature2–8°C
    36 months24 months36 months24 months
    pH (reconstituted)7.47.47.45.6
    ExcipientsIn 100 U vial:In 500 U vial:In 100 U vial:HSA 500 μg/ml
    HSA 500 μgHSA 125 μgHSA 1000 μgSuccinate 10 mM
    NaCl (900 μg/vial)Lactose (2.5 mg/vial)Sucrose (4.7 mg/vial)NaCl 100 mM
    Unit/vial100 U or 200 U Botox300 U or 500 U Dysport100 U or 200 U Xeomin2500 U/0.5 ml
    50 U Vistabel125 U Azzalure50 U Bocouture5000 U/1 ml
    10,000 U/2 ml
    Protein load/vial5 ng/100 U4.35 ng/500 U0.44 ng/100 Ua55 ng/2500 U
    Clinical activity in relation to Botox11:2–1:311:40–1:50
    • HSA, human serum albumin; PTC, progenitor toxin complex.

    • ↵a Neurotoxin concentration measured by ELISA (Frevert, 2010).

    • View popup
    TABLE 5

    Therapeutic uses for botulinum neurotoxin

    Ophtalmology
     Strabismusa,b,c
     Nistagmus
    Neurology
     Focal Dystonias
      Blepharospasma,b,c
      Cervical dystoniaa,b,c (Torticollis, anterocollis, laterocollis)
      Occupational dystonias (writer’s crampb, musician’s cramps)
      Laryngeal Dysphoniac
      Oromandibular dystonia
      Lingual dystonia
     Nondystonic disorders
      Hemifacial spasma,b,c
      Tremor (essential, parkinsonism)
      Tics
      Bruxism
     Spasticity (poststroke, multiple sclerosis, brain or spinal cord injury)
      Focal spasticitya,b,c: Upper and lower limb spasticity
      Nonfocal: hemispasticity, paraspasticity, tetraspasticity
      Cerebral palsyab
     Hyperhidrosisa,b,c
      Focal: axillary, palmar, plantar
      Diffuse
     Hypersalivation
      Sialorrheab (motoneuron diseases/amyotrophic lateral sclerosis)
      Droolingb (Parkinsonian syndromes)
      Frey’s syndrome/gustatory sweating
     Aesthetic (muscle)
      Glabellar rythidesa,b,c
    Pain
     Muscular
      Dystonia
      Spasticity
      Chronic myofascial pain
      Temporomandibular disorders
      Low back pain
     Nonmuscular
      Migraine (chronica and tension type migraine)
      Neuropathic pain
      Trigeminal pain
      Pelvic pain
    Urology
     Detrusor sphincter dyssynergia
     Overactive bladdera,b,c (Idiopathic or neurogenic detrusor  overactivity)
     Urinary retention
     Bladder pain syndrome
     Pelvic floor spasms
     Benign prostate hyperplasia
    Gastroenterology
     Achalasia
     Chronic anal fissures
    Psychiatry
     Depressiond
    • ↵a USA approved indication.

    • ↵b EU approved indication.

    • ↵c Evidence-based therapeutic indication.

    • ↵d To be evaluated.

    • View popup
    TABLE 6

    Toxicity of BoNTs in mice upon i.p. injection expressed as LD50 (ng/kg)

    Toxin TypeLD50Reference
    BoNT/A11.15aDuff, et al., 1957a
    0.45Nakamura et al., 2010
    0.38Pier et al., 2011
    0.40Whitemarsh et al., 2013
    0.40Pellett et al., 2015b
    0.25Azarnia Tehran et al., 2015
    BoNT/A20.11Pier et al., 2011
    0.39Whitemarsh et al., 2013
    BoNT/A30.35Whitemarsh et al., 2013
    BoNT/A4400–500Whitemarsh et al., 2013
    BoNT/A50.35Whitemarsh et al., 2013
    BoNT/B11.93aLamanna and Glassman, 1947
    1.23aDuff, et al., 1957b
    0.41Nakamura et al., 2010
    0.45bAzarnia Tehran et al., 2015
    BoNT/B20.40Fan et al., 2016
    BoNT/C15.00Notermans et al., 1982
    2.30Tsukamoto et al., 2005
    1.65Morbiato et al., 2007
    0.92Nakamura et al., 2010
    BoNT/CD1.42Notermans et al., 1982
    1.80Matsuda et al., 1986
    1.92Tsukamoto et al., 2005
    0.80Nakamura et al., 2010
    BoNT/D0.15Tsukamoto et al., 2005
    0.18Nakamura et al., 2010
    0.83Eleopra et al., 2013
    0.43Pellett et al., 2015b
    0.02bAzarnia Tehran et al., 2015
    BoNT/DC0.05Nakamura et al., 2010
    BoNT/E10.65Pier et al., 2011
    0.84Chatla et al., 2012
    1.00Meunier et al., 2003
    BoNT/F12.50Oishi and Sakaguchi, 1974
    10.0Meunier et al., 2003
    BoNT/FA2.20Fan et al., 2016
    1.30Maslanka et al., 2016
    BoNT/G5.00Schiavo et al., 1994
    • ↵a BoNT complexed as PTC.

    • ↵b Toxins produced by recombinant methods.

PreviousNext
Back to top

In this issue

Pharmacological Reviews: 69 (2)
Pharmacological Reviews
Vol. 69, Issue 2
1 Apr 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

Biological Actions of Botulinum Neurotoxins

Marco Pirazzini, Ornella Rossetto, Roberto Eleopra and Cesare Montecucco
Pharmacological Reviews April 1, 2017, 69 (2) 200-235; DOI: https://doi.org/10.1124/pr.116.012658

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview Article

Biological Actions of Botulinum Neurotoxins

Marco Pirazzini, Ornella Rossetto, Roberto Eleopra and Cesare Montecucco
Pharmacological Reviews April 1, 2017, 69 (2) 200-235; DOI: https://doi.org/10.1124/pr.116.012658
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Biology
    • III. Pharmacology
    • IV. Toxicity of Botulinum Neurotoxins
    • V. Conclusions
    • Acknowledgments
    • Authorship Contributions:
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Quest to Define and Target Cellular Senescence
  • Nanozymes for viral diagnosis and therapy
  • Structure and Inhibition of NLRP3 Inflammasome
Show more Review Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics